Aspects of the treatment of Turner syndrome

Bibliography

• TURNER HH: A syndrome of infantilism, congenital webbed neck, and cubitus valgus. Endocrinology (1938) 23:566–574.
   Google Scholar
• SERESEVSKIJ NA: In relation to the question of a connection between congential abnormalities and endocrinopathies. (1925).
   Google Scholar
• LONBERG NC NIELSEN J: Seresevskij-Turner's syndrome or Turner's syndrome [letter]. Hum. Genet. (1977) 38(3):363–364.
   PubMedGoogle Scholar
• ULLRICH O: Uber typische multipler abartungen. Kinderheilkd. (1930) 49:271–276.
   Google Scholar
• OPITZ JM PALLISTER PD: Brief historical note: the concept of 'gonadal dysgenesis'. Am. j Med. Genet. (1979) 4(4)333–343.
   Google Scholar
• GRAVHOLT CH, JUUL S, NAERAA RW, J: Morbidity in Turner syndrome. j Clin. Epidemic]. (1998) 51(2):147–158.
   PubMed Web of Science ®Google Scholar
• HELD KR, KERBER S, KAMINSKY E,SINGH S, GOETZ P, SEEMANOVA E, GOEDDE HW: Mosaicism in 45,X Turner syndrome: does survival in early pregnancy depend on the presence of two sex chromosomes? Hum. Genet. (1992) 88:288–294.
   Google Scholar
• FERNANDEZ R, MENDEZ J, PASARO E: Turner syndrome: a study of chromosomal mosaicism. Hum. Genet. (1996) 98(1):29–35.
   PubMedGoogle Scholar
• JACOBS PA, MELVILLE M, RATCLIFFE S, KEAY AJ, SYME J: A cytogenetic survey of 11,680 newborn infants. Ann. Hum. Genet. (1974) 37:359–376.
   PubMed Web of Science ®Google Scholar
• HOOK EB WARBURTON D: The distribution of chromosomal genotypes with Turner's syndrome: livebirth prevalence rates and evidence for diminished fetal mortality and severity in genotypes associated with structural X abnormalities or mosaicism. Hum. Genet. (1983) 64:24–27.
   PubMedGoogle Scholar
• NIELSEN J WOHLERT M: Chromosome abnormalities found among 34,910 newborn children: results from a 13-year incidence study in Arhus, Denmark. Hum. Genet. (1991) 87:81–83.
   PubMedGoogle Scholar
• IMAIZUMI K, KUROKI Y: In: Prevalence of Turner Syndrome in Japan. Hibi I, Takano K (Eds.), Excerpta Medica, Amsterdam (1993):3–6.
   Google Scholar
• GRAVHOLT CH, JUUL S, NAERAA RW, HANSEN J: Prenatal and postnatal prevalence of Turner's syndrome: a registry study. Br. Med. J. (1996) 312:16–21.
   PubMed Web of Science ®Google Scholar
• ROSENFELD RG, ATTIE KM, FRANE J et al.: Growth hormone therapy of Turner's syndrome: beneficial effect on adult height. Pediatr. (1998) 132(2):319–324.
   Google Scholar
• TAKANO K, SHIZUME K, HIBI I et al:Long-term effects of growth hormone treatment on height in Turner syndrome: results of a 6-year multicentre study in Japan. Committee for the Treatment of Turner Syndrome. Herm. Res. (1995) 43:141–143.
   Google Scholar
• RANKE MB, PFLUGER H, W et al.: Turner syndrome: spontaneous growth in 150 cases and review of the literature. Eur. j Pediatr. (1983) 141:81–88.
   PubMedGoogle Scholar
• SYBERT VP: Adult height in Turner with and without androgen therapy. j Pediatr. (1984) 104:365–369.
   PubMedGoogle Scholar
• LYON AJ, PREECE MA, GRANT DB: Growth curve for girls with Turner syndrome. Arch. Dis. Child (1985) 60(10):932–935.
   PubMedGoogle Scholar
• SUWA S: Standards for growth and growth in Turner's syndrome. Acta Paediatr. Jpri. (1992) 34:206–220.
   PubMedGoogle Scholar
• ROCHICCIOLI P, DAVID M, G et al: Study of final height in Turner's syndrome: ethnic and genetic influences. Acta Paediatr (1994) 83:305–308.
   PubMedGoogle Scholar
• GARCIA RUDAZ C, MARTINEZ AS, HEINRICH JJ etal.: Growth of Argentinian girls with Turner syndrome. Ann. Hum. Biol. (1995) 22(6):533–544.
   Google Scholar
• LOW LC, SHAM C, KWAN E et al: Spontaneous growth in Chinese patients with Turner's syndrome and influence of karyotype. Acta Paediatr. (1997) 86(1):18–
   PubMedGoogle Scholar
• RONGEN WESTERLAKEN C, COREL, VAN DEN BROECK J et al: Reference values for height, height velocity and weight in Turner's syndrome. Swedish Study Group for GH treatment. Acta Paediatr. (1997) 86(9):937–942.
   PubMedGoogle Scholar
• GRAVHOLT CH, NAERAA RW: Reference values for body proportions and body composition in adult women with Turner's syndrome. Am. j Med. Genet. (1997) 72:403–408.
   PubMed Web of Science ®Google Scholar
• KARLBERG J, ALBERTSSON WK, NILSSON KO, RITZEN EM, WESTPHAL 0: Growth in infancy and childhood in girls with Turner's syndrome. Acta Paediatr. Scand. (1991) 80:1158–1165.
   PubMedGoogle Scholar
• DAVENPORT ML, PUNYASAVATSUT N, GUNTHER D, SAVENDAHL L, PW: Turner syndrome: a pattern of early growth failure. Acta Paediatr. Suppl. (1999) 88(433):118–121.
   PubMedGoogle Scholar
• PASQUINO AM, PASSERI F, I, SEGNI M, MUNICCHI G: Spontaneous pubertal development in Turner's syndrome. Italian Study Group for Turner's Syndrome. I Chu. Endocrine]. Metab. (1997) 82(6):1810–1813.
   Google Scholar
• HOVATTA O: Pregnancies in women withTurner's syndrome. Ann. Med. (1999) 31(2):106–110.
   PubMed Web of Science ®Google Scholar
• MASSARANO AA, BROOK CG, HINDMARSH PC et al: Growth hormone secretion in Turner's syndrome and influence of oxandrolone and ethinyl oestradiol. Arch. Dis. Child. (1989) 64:587–592.
   PubMedGoogle Scholar
• REITER JC, CRAEN M, VAN VLIET G:Decreased growth hormone response to growth hormone-releasing hormone in Turner's syndrome: relation to body weight and adiposity. Acta Endocrine]. (1991) 125:38–42.
   PubMedGoogle Scholar
• RANKE MB, BLUM WE HAUG E ROSENDAHL W et al.: Growth hormone, somatomedin levels and growth regulation in Turner's syndrome. Acta Endocrine]. (1987) 116:305–313.
   Google Scholar
• SAENGER P, SCHWARTZ E, E, LEVINE LS, TSAI M, NEW MI: The interaction of growth hormone, somatomedin and oestrogen in patients with Turner's syndrome. Acta Endocrine]. (1976) 81:9–18.
   PubMedGoogle Scholar
• WIT JM, MASSARANO AA, KAMP GA et al: Growth hormone secretion in patients with Turner's syndrome as determined by time series analysis. Acta Endocrine]. (1992) 127:7–12.
   PubMedGoogle Scholar
• FOSTER CM, BORONDY M, MARKOVS ME, HOPWOOD NJ, KLETTER GB, BEITINS IZ: Growth hormone bioactivity in girls with Turner's syndrome: correlation with insulin-like growth Factor I. Pediatr. Res. (1994) 35:218–222.
   PubMedGoogle Scholar
• BLETHEN SL, ALBERTSSON K, FAKLIS EJ, CHASALOW Fl: Circulating growth hormone isoforms in girls with Turner's syndrome. I Chu. Endocrine]. Metab. (1994) 78:1439–1443.
   PubMedGoogle Scholar
• ISHIKAWA M, YOKOYA S, K etal.: Serum levels of 20-kilodalton human growth hormone (GH) are parallel those of 22-kilodalton human GH in normal and short children. j Chu. Endocrine]. Metab. (1999) 84(1):98–104.
   Google Scholar
• ROSS JL, LONG LM, LORIAUX DL, CUTLER GBJ: Growth hormone secretory dynamics in Turner syndrome. J. Pediatr. (1985) 106:202–206.
   PubMedGoogle Scholar
• ZADIK Z, LANDAU H, CHEN M, ALTMAN Y, LIEBERMAN E: Assessment of growth hormone (GH) axis in Turner's syndrome using 24-hour integrated concentrations of GH, insulin-like growth factor-I, plasma GH-binding activity, GH binding to IM9 cells, and GH response to pharmacological stimulation. j Chu. Endocrine]. Metab. (1992) 75:412–416.
   PubMedGoogle Scholar
• DAUGHADAY WH, ROTWEIN P: Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Eridocr. Rev (1989) 10(1):68–91.
   Google Scholar
• ROSS JL, CASSORLA FG, SKERDA MC, VALK IM, LORIAUX DL, CUTLER GBJ: A preliminary study of the effect of estrogen dose on growth in Turner's syndrome. N Engl. J. Med. (1983) 309:1104–1106.
   PubMed Web of Science ®Google Scholar
• CUTTLER L, VAN VLIET G, CONTE FA, KAPLAN SL, GRUMBACH MM: Somatomedin-C levels in children and adolescents with gonadal dysgenesis: differences from age-matched normal females and effect of chronic estrogen replacement therapy. j Chu. Endocrine]. Metab. (1985) 60:1087–1092.
   PubMed Web of Science ®Google Scholar
• WIEDEMANN E, SCHWARTZ E, FRANTZ AG: Acute and chronic estrogen effects upon serum somatomedin activity, growth hormone, and prolactin in man. Chu. Endocrine]. Metab. (1976) 42(5):942–952.
   PubMedGoogle Scholar
• GRAVHOLT CH, NAERAA RW, FISKER S, CHRISTIANSEN JS: Body composition and physical fitness are major determinants of the growth hormone-IGF axis aberrations in adult Turner syndrome, with important modulations by treatment with 17-beta-estradiol. j Chu. Endocrine]. Metab. (1997) 82 (8) :2570–2577.
   PubMedGoogle Scholar
• WESTWOOD M, GIBSON JM, WILLIAMS AC et al: Hormonal regulation of circulating insulin-like growth factor-binding protein-1 phosphorylation status. Chu. Endocrine]. Metab. (1995) 80(12):3520–3527.
   PubMedGoogle Scholar
• WESTWOOD M, GIBSON JM, PENNELLS LA, WHITE A: Modification of plasma insulin-like growth factors and binding proteins during oral contraceptive use and the normal menstrual cycle. Am. Obstet. Gyriecol (1999) 180(3 Pt 0:530–536.
   Google Scholar
• COX GN, MCDERMOTT MJ, MERKEL E et al.: Recombinant human insulin-like growth factor (IGF)-binding protein-1 inhibits somatic growth stimulated by IGF- and growth hormone in rats. Endocrinology (1994) 135(5):1913–1920.
   PubMedGoogle Scholar
• GRAVHOLT CH, FRYSTYK J, FLYVBJERG A, ORSKOV H, CHRISTIANSEN JS: Reduced free IGF-I and increased IGFBP-3 proteolysis in Turner syndrome: modulation by female sex steroids. Am. j Physiol (2001) 280:E308–E314.
   Google Scholar
• BAXTER RC: Insulin-like growth factor (IGF)-binding proteins: interactions with IGEs and intrinsic bioactivities. Am. Physiol Endocrinol Metab. (2000) 278(6):E967–E976.
   Google Scholar
• HOCHBERG Z, AVIRAM M, RUBIN D, POLLACK S: Decreased sensitivity to insulin-like growth Factor Tin Turner's syndrome: a study of monocytes and T lymphocytes. Eur. j CM]. Invest. (1997) 27(7):543–547.
   PubMedGoogle Scholar
• GRAVHOLT CH, VELDHUIS JD, CHRISTIANSEN JS: Increased disorderliness and decreased mass and daily rate of endogenous growth hormone secretion in adult Turner syndrome: the impact of body composition, maximal oxygen uptake and treatment with sex hormones. Growth Horm. IGF Res. (1998) 8(4):289–298.
   PubMedGoogle Scholar
• PINCUS SM, GEVERS EE ROBINSON IC etal.: Females secrete growth hormone with more process irregularity than males in both humans and rats. Am. j Physiol. (1996) 270(33):E107–E115.
   Google Scholar
• APTER D, LENKO HL, J, SODERHOLM A, VIHKO R: Subnormal pubertal increases of serum androgens in Turner's syndrome. Horm. Res. (1982) 16(3):164–173.
   PubMedGoogle Scholar
• GRAVHOLT CH, SVENSTRUP B, BENNETT P, CHRISTIANSEN JS: Low androgen levels in adult Turner syndrome: influence of female sex hormones and growth hormone status. OM Eric/or/Mal Oxf (1999) 50:791–800.
   Google Scholar
• ROSENFELD RG, HINTZ RL, AJ et al: Three-year results of a randomized prospective trial of methionyl human growth hormone and oxandrolone in Turner syndrome. j Pediatr. (1988) 113:393–400.
   PubMed Web of Science ®Google Scholar
• NAERAA RW, NIELSEN J, KASTRUP KW: Treatment of girls with Turner's syndrome with growth hormone and estrogen--1-year experiences. Ugeskr. Laeger (1992) 154:1773–1778.
   PubMedGoogle Scholar
• HAEUSLER G, SCHMITT K, BLUMEL P, PLOCHL E, WALDHOR T, FRISCH H: Growth hormone in combination with anabolic steroids in patients with Turner syndrome: effect on bone maturation and final height. Acta Paediatr. (1996) 85(12):1408–1414.
   PubMedGoogle Scholar
• TABACK SP, COLLU R, DEAL CL et al: Does growth-hormone supplementation affect adult height in Turner's syndrome? Lancet (1996) 348(9019):25–27.
   PubMedGoogle Scholar
• ROCHICCIOLI P, BATTIN J, BERTRAND AM et al: Final height in Turner syndrome patients treated with growth hormone. Horm. Res. (1995) 44(4):172–176.
   PubMedGoogle Scholar
• VAN DEN BROECK J, MASSA GG, ATTANASIO A et al.: Final height after long-term growth hormone treatment in Turner syndrome. European Study Group. Pediatr. (1995) 127:729–735.
   Google Scholar
• DACOU VC, KARAVANAKI V, GEORGOPOULOS N, MANIATI CM, MAVROU A: The growth pattern and final height of girls with Turner syndrome with and without human growth hormone treatment. Pediatrics (1998) 101(4 Pt 1):663–668.
   Google Scholar
• PASQUINO AM, PASSERI F, MUNICCHI G et al: Final height in Turner syndrome patients treated with growth hormone. Horm. Res. (1996) 46(6):269–272.
   PubMedGoogle Scholar
• TAKANO K, OGAWA M, TANAKA T, TACHIBANA K, FUJITA K, HIZUKA N: Clinical trials of GH treatment in patients with Turner's syndrome in Japan--a consideration of final height. The Committee for the Treatment of Turner's Syndrome. Eur. j Eridocrinol. (1997) 137(2):138–145.
   Google Scholar
• NILSSON KO, ALBERTSSON WIKLAND K, ALM J et al: Improved final height in girls with Turner's syndrome treated with growth hormone and oxandrolone. j Chia. Endocrinol Metab. (1996) 81(2):635–640.
   PubMed Web of Science ®Google Scholar
• CHU CE, PATERSON WF, KELNAR CJ, SMAIL PJ, GREENE SA, DONALDSON MD: Variable effect of growth hormone on growth and final adult height in Scottish patients with Turner's syndrome. Acta Paediatr. (1997) 86(2):i60–i64.
   Google Scholar
• HOCHBERG Z, ZADIK Z: Final heightin young women with Turner syndrome after GH therapy: an open controlled study. Eur. Eric/or/Ma (1999) 141(3):218–224.
   Google Scholar
• CACCIARI E, MAZZANTI L: Final height of patients with Turner's syndrome treated with growth hormone (GH): indications for GH therapy alone at high doses and late estrogen therapy. Italian Study Group for Turner Syndrome. j CM]. Endocrinol Metab (1999) 84(12):4510–4515.
   PubMedGoogle Scholar
• CAREL JC, MATHIVON L, GENDREL, DUCRET JP, CHAUSSAIN JL: Near normalization of final height with adapted doses of growth hormone in Turner's syndrome. j CM]. Eridocrinol. Metab. (1998) 83(5):1462–1466.
   PubMedGoogle Scholar
• SAS TC, MUINCK KEIZER-SCHRAMA SM, STIJNEN T et al: Normalization of height in girls with Turner syndrome after long-term growth hormone treatment: results of a randomized dose-response trial. CM]. Eridocrinol. Metab (1999) 84(12):4607–4612.
   PubMedGoogle Scholar
• BROWN DM, JOWSEY J, BRADFORD DS: Osteoporosis in ovarian dysgenesis. Pediatr. (1974) 84:816–820.
   Google Scholar
• STEPAN JJ, MUSILOVA J, PACOVSKY: Bone demineralization, biochemical indices of bone remodeling, and estrogen replacement therapy in adults with Turner's syndrome. j Bone Miner. Res. (1989) 4:193–198.
   PubMed Web of Science ®Google Scholar
• SHORE RIVI, CHESNEY RW, MAZESS RB, ROSE PG, BARGMAN GJ: Skeletal demineralization in Turner's syndrome. Cakif Tissue Int. (1982) 34:519–522.
   PubMedGoogle Scholar
• KURABAYASHI T, YASUDA M, FUJIMAKI T, YAMAMOTO Y, ODA K, TANAKA K: Effect of hormone replacement therapy on spinal bone mineral density and T lymphocyte subsets in premature ovarian failure and Turner's syndrome. Int. J. Gyriaecol Obstet. (1993) 42:25–31.
   PubMedGoogle Scholar
• DAVIES MC, GULEKLI B, JACOBS HS: Osteoporosis in Turner's syndrome and other forms of primary amenorrhoea. OM. Endocrinol °xi (1995) 43(6):741–746.
   Google Scholar
• EVEN L, BRONSTEIN V, HOCHBERG Z: Bone maturation in girls with Turner's syndrome. Eur. Eric/or/Ma (1998) 138(1):59–62.
   Google Scholar
• NAERAA RW, BRIXEN K, HANSEN RIVI et al: Skeletal size and bone mineral content in Turner's syndrome: relation to karyotype, treatment, physical fitness, and bone turnover. CaIcif Tissue Int. (1991) 49:77–83.
   PubMed Web of Science ®Google Scholar
• MORA S, WEBER G, GUARNERI MP, NIZZOLI G, PASOLINI D, CHIUMELLO G: Effect of estrogen replacement therapy on bone mineral content in girls with Turner syndrome. Obstet. Gyrrecol (1992) 79:747–751.
   Google Scholar
• MAURAS N, VIEIRA NE, YERGEY AL: Estrogen therapy enhances calcium absorption and retention and diminishes bone turnover in young girls with Turner's syndrome: a calcium kinetic study. Metabolism (1997) 46(8):908–913.
   PubMedGoogle Scholar
• EMANS SJ, GRACE E, HOFFER FA, GUNDBERG C, RAVNIKAR V, WOODS ER: Estrogen deficiency in adolescents and young adults: impact on bone mineral content and effects of estrogen replacement therapy. Obstet. Gyrrecol (1990) 76:585–592.
   Google Scholar
• CARRASCOSA A, GUSSINYE M, TERRADAS P, YESTE D, AUDI L, VICENS-CALVET E: Spontaneous, but not induced, puberty permits adequate bone mass acquisition in adolescent Turner syndrome patients. I Bone Miler. Res. (2000) 15(10):2005–2010.
   PubMedGoogle Scholar
• NEELY EK, MARCUS R, ROSENFELD RG, BACHRACH LK: Turner syndrome adolescents receiving growth hormone are not osteopenic. j Chi]. Endocrinol Metab. (1993) 76:861–866.
   PubMedGoogle Scholar
• LANES R, GUNCZLER P, PAOLI M, WEISINGER JR: Bone mineral density of prepubertal age girls with Turner's syndrome while on growth hormone therapy. Harm. Res. (1995) 44:168–171.
   PubMedGoogle Scholar
• CAPRIO S, BOULWARE SD, PRESS Met al.: Effect of growth hormone treatment on hyperinsulinemia associated with Turner syndrome. I Pediatr. (1992) 120:238–243.
   Google Scholar
• SAS TC, MUINCK KEIZER-SCHRAMA SM, STIJNEN T, AANSTOOT HJ, DROP SL: Carbohydrate metabolism during long-term growth hormone (GH) treatment and after discontinuation of GH treatment in girls with Turner syndrome participating in a randomized dose-response study. Dutch Advisory Group on Growth Hormone. j Cliii. Endocnnol Metab. (2000) 85(2):769–775.
   PubMed Web of Science ®Google Scholar
• SAENGER E ATTIE KM, DIMARTINO NARDI J, FINE RN: Carbohydrate metabolism in children receiving growth hormone for 5 years. Chronic renal insufficiency compared with growth deficiency, Turner syndrome, and idiopathic short stature. Genentech Collaborative Group. Pediatr Nephrol (1996) 10(3):261–263.
   Google Scholar
• SYBERT VP: Cardiovascular malformationsand complications in Turner syndrome. Pediatrics (1998) 101(1):E11.
   PubMed Web of Science ®Google Scholar
• GOTZSCHE CO, KRAG OLSEN B, NIELSEN J, SORENSEN KE, KRISTENSEN BO: Prevalence of cardiovascular malformations and association with karyotypes in Turner's syndrome. Arch. Dis. Child (1994) 71:433–436.
   PubMed Web of Science ®Google Scholar
• DAWSON FKL, WRIGHT AM, BAKKER B, PITLICK PT, ROSENFELD RG: Cardiovascular evaluation in Turner syndrome: utility of MR imaging. Australas. Radial. (1992) 36:204–209.
   PubMedGoogle Scholar
• BORDELEAU L, CWINN A, TUREK M, BARRON la, VICTOR G: Aortic dissection and Turner's syndrome: case report and review of the literature. I Emerg. Med. (1998) 16(4):593–596.
   Google Scholar
• LIN AE, LIPPE B, ROSENFELD RG: Further Delineation of Aortic Dilation, Dissection, and Rupture in Patients With Turner Syndrome. Pediatr. Electron Pages (1998) 102(1):e12.
   Google Scholar
• ELSHEIKH M, CASADEI B, CONWAY GS, WASS JA: Hypertension is a major risk factor for aortic root dilatation in women with Turner's syndrome. OM. Endocrinol (Ox!) (2001) 54(1):69–73.
   PubMed Web of Science ®Google Scholar
• SAS TC, CROMME-DIJKHUIS AH, DE MUINCK K, STIJNEN T, VAN TEUNENBROEK A, DROP SL: The effects of long-term growth hormone treatment on cardiac left ventricular dimensions and blood pressure in girls with Turner's syndrome. j Pediatr. (1999) 135(4):470–476.
   PubMedGoogle Scholar
• GERVER WJ, DRAYER NM, VAN ES A: Does growth hormone treatment of patients with Turner's syndrome cause an abnormal body shape? Acta Paediatr. (1992) 81:691–694.
   Google Scholar
• SAS TC, GERVER WJ, DE BRUIN R etal.: Body proportions during long-term growth hormone treatment in girls with Turner syndrome participating in a randomized dose-response trial. ..J. OM. Endocnnol Metab. (1999) 84(12):4622–4628.
   Google Scholar
• NAERAA RW, NIELSEN J, KASTRUP KW: Growth hormone and 17 beta-oestradiol treatment of Turner girls-- 2-year. Eur. j Pediatr. (1994) 153:72–77.
   PubMedGoogle Scholar
• ROSENFELD RG, FRANE J, ATTIE KM et al.: Six-year results of a randomized, prospective trial of human growth hormone and oxandrolone in Turner syndrome. Pediatr. (1992) 121:49–55.
   Google Scholar
• HAEUSLER G, SCHMITT K, BLUMEL P, PLOCHL E, WALDHOR T, FRISCH H: Insulin, insulin-like growth factor-binding protein-1, and sex hormone-binding globulin in patients with Turner's syndrome: course over age in untreated patients and effect of therapy with growth hormone alone and in combination with oxandrolone. j Cliii. Endocrinol Metab. (1996) 81(2):536–541.
   PubMedGoogle Scholar
• SYLVEN L, MAGNUSSON C, K, VON SCHOULTZ B: Life with Turner's syndrome--a psychosocial report from 22 middle-aged women. Acta Endocrinol Coperrh. (1993) 129:188–194.
   PubMedGoogle Scholar
• BOECHAT MI, WESTRA SJ, LIPPE B:Normal US appearance of ovaries and uterus in four patients with Turner's syndrome and 45,X karyotype. Pediatr. Radial. (1996) 26:37–39.
   PubMedGoogle Scholar
• CHERNAUSEK SD, ATTIE KM, CARA JF, ROSENFELD RG, FRANE J: Growth hormone therapy of Turner syndrome: the impact of age of estrogen replacement on final height. Genentech, Inc., Collaborative Study Group. I OM. Endocnnol Metab. (2000) 85(7):2439–2445.
   PubMedGoogle Scholar
• KHASTGIR G, ABDALLA H, THOMAS A, KOREA L, LATARCHE L, STUDD J: Oocyte donation in Turner's syndrome: an analysis of the factors affecting the outcome. Hum. Reprod. (1997) 12(2):279–285.
   PubMedGoogle Scholar
• FOUDILA T, SODERSTROM A, V, HOVATTA 0: Turner's syndrome and pregnancies after oocyte donation. Hum. Reprod. (1999) 14(2):532–535.
   PubMedGoogle Scholar
• YARON Y, OCHSHORN Y, AMIT A, YOVEL I, KOGOSOWKI A, LESSING JB: Patients with Turner's syndrome may have an inherent endometrial abnormality affecting receptivity in oocyte donation. Perth. Steril. (1996) 65(6):1249–1252.
   PubMed Web of Science ®Google Scholar
• PELZ L, SAGER G, HINKEL GK, KIRCHNER M, KRUGER G, VERRON G: Delayed spontaneous pubertal growth spurt in girls with the Ullrich-Turner syndrome. Am. J. Med. Genet. (1991) 40:401–405.
   PubMedGoogle Scholar
• PARK E, BAILEY JD, COWELL CA: Growth and maturation of patients with Turner's syndrome. Pediatr. Res. (1983) 17:1–7.
   PubMed Web of Science ®Google Scholar
• PARK E: Body shape in Turner's syndrome. Hum. Biol. (1977) 49:215–223.
   PubMed Web of Science ®Google Scholar
• VARRELA J, VINKKA H, ALVESALO L: The phenotype of 45,X females: an anthropometric quantification. Ann. Hum. Biol. (1984) 11:53–66.
   PubMed Web of Science ®Google Scholar
• HOLL RW, KUNZE D, ETZRODT H, TELLER W, HEINZE E: Turner syndrome: final height, glucose tolerance, bone density and psychosocial status in 25 adult patients. Eur. j Pediatr. (1994) 153:11–16.
   PubMed Web of Science ®Google Scholar
• BURGER HG, DUDLEY EC, HOPPER JL et al: The endocrinology of the menopausal transition: a cross- sectional study of a population-based sample. I Clin. Endocrinol Metab. (1995) 80(12):3537–3545.
   PubMedGoogle Scholar
• JENSEN J, CHRISTIANSEN C, RODBRO P: Oestrogen-progestogen replacement therapy changes body composition in early post-menopausal women. Matztritas (1986) 8:209–216.
   PubMedGoogle Scholar
• REBUFFE SCRIVE M, LONNROTH P, MARIN P, WESSLAU C, BJORNTORP P, SMITH U: Regional adipose tissue metabolism in men and postmenopausal women. Int.j Obes. (1987) 11(4):347–355.
   PubMedGoogle Scholar
• HAARBO J, MARSLEW U, A, CHRISTIANSEN C: Postmenopausal hormone replacement therapy prevents central distribution of body fat after menopause. Metabolism (1991) 40(12):1323–1326.
   PubMed Web of Science ®Google Scholar
• GAMBACCIANI M, CIAPONI M, CAPPAGLI B et al: Body weight, body fat distribution, and hormonal replacement therapy in early postmenopausal women. Clin. Eric/or/Ma Metab. (1997) 82:414–417.
   PubMed Web of Science ®Google Scholar
• REBUFFE SCRIVE M, ELDH J, HAFSTROM LO, BJORNTORP P: Metabolism of mammary, abdominal, and femoral adipocytes in women before and after menopause. Metabolism (1986) 35(9):792–797.
   PubMedGoogle Scholar
• DALLONGEVILLE J, MARECAUX N, ISOREZ D, ZYLBERGBERG G, FRUCHART JC, AMOUYEL P: Multiple coronary heart disease risk factors are associated with menopause and influenced by substitutive hormonal therapy in a cohort of French women. Atherosclerosis (1995) 118(1):123–133.
   PubMedGoogle Scholar
• GRAVHOLT CH, NAERAA RW, NYHOLM B et al.: Glucose metabolism, metabolism, and cardiovascular risk factors in adult Turner syndrome: the impact of sex hormone replacement. Diabetes Care (1998) 21(7):1062–1070.
   PubMed Web of Science ®Google Scholar
• BERNTORP K, ERIKSSON KF, LINDGARDE F: The importance of diabetes heredity in lean subjects on insulin secretion, blood lipids and oxygen uptake in the pathogenesis of glucose intolerance. Diabetes Res. (1986) 3:231–236.
   PubMedGoogle Scholar
• BERNTORP K, LINDGARDE F: Impaired physical fitness and insulin secretion in normoglycaemic subjects with familial aggregation of Type 2 diabetes mellitus. Diabetes Res. (1985) 2(3):151–156.
   PubMedGoogle Scholar
• NYHOLM B, MENGEL A, NIELSEN Set al.: Insulin resistance in relatives in relatives of NIDDM patients: the role of physical fitness and muscle metabolism. Diabetologia (1996) 39:813–822.
   Google Scholar
• BECK NIELSEN H GROOP LC: Metabolic and genetic characterization of prediabetic states. Sequence of events leading to non-insulin-dependent diabetes mellitus. J. Chit. Invest. (1994) 94(5):1714–1721.
   Google Scholar
• MARIN P, ANDERSSON B, KROTKIEWSKI M, BJORNTORP P: Muscle fiber composition and capillary density in women and men with NIDDM. Diabetes Care (1994) 17(5):382–386.
   PubMed Web of Science ®Google Scholar
• SALTIN B STRANGE S: Maximal oxygen uptake: 'old' and new' arguments for a cardiovascular limitation. Med. Sci. Sports Exerc. (1992) 24(1):30–37.
   PubMedGoogle Scholar
• GRAVHOLT CH, NYHOLM B, SALTIN B, SCHMITZ 0, CHRISTIANSEN JS: Muscle fiber composition and capillary density in Turner syndrome: Evidence of increased muscle fiber size related to insulin resistance. Diabetes Care (2001). (In Press).
   Google Scholar
• RUTHERFORD OM, JONES DA: The relationship of muscle and bone loss and activity levels with age in women. Age. Ageing (1992) 21(4):286–293.
   PubMedGoogle Scholar
• PHILLIPS SK, ROOK KM, SIDDLE NC, BRUCE SA, WOLEDGE RC: Muscle weakness in women occurs at an earlier age than in men, but strength is preserved by hormone replacement therapy. Chit. Li. Col& (1993) 84(1):95–98.
   Google Scholar
• HORSMAN A, JONES M, FRANCIS R, NORDIN C: The effect of estrogen dose on postmenopausal bone loss. N Engl. I Med. (1983) 309:1405–1407.
   PubMed Web of Science ®Google Scholar
• WESTERVELD HT, KOCK LA, VAN RIJN HJ, ERKELENS DW, DE BRUIN: 17 beta-Estradiol improves postprandial lipid metabolism in postmenopausal women. j Chit. Eric/or/Ma Metab. (1995) 80:249–253.
   PubMedGoogle Scholar
• FARISH E, ROLTON HA, BARNES JF et al.: Lipoprotein(a) and postmenopausal oestrogen. Acta Endocnitol. Copenh. (1993) 129:225–228.
   PubMedGoogle Scholar
• GODSLAND IF, GANGAR K, WALTON et al: Insulin resistance, secretion, and elimination in postmenopausal women receiving oral or transdermal hormone replacement therapy. Metabolism (1993) 42:846–853.
   PubMed Web of Science ®Google Scholar
• STEVENSON JC, CUST MP, GANGAR KF, HILLARD TC, LEES B, WHITEHEAD MI: Effects of transdermal versus oral hormone replacement therapy on bone density in spine and proximal femur in postmenopausal women. Lancet (1990) 336:265–269.
   PubMed Web of Science ®Google Scholar
• YKI JARVINEN H: Role of insulin resistance in the pathogenesis of NIDDM. Diabetologia (1995) 38:1378–1388.
   PubMedGoogle Scholar
• GRADY D, RUBIN SM, PETITTI DB et al.: Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann. Intern. Med. (1992) 117(12):1016–1037.
   PubMed Web of Science ®Google Scholar
• CAGNACCI A, SOLDANI R, CARRIERO PL, PAOLETTI AM, FIORETTI P, MELIS GB: Effects of low doses of transdermal 17 beta-estradiol on carbohydrate metabolism in postmenopausal women. j Chit. Eric/or/Ma Metab. (1992) 74:1396–1400.
   PubMed Web of Science ®Google Scholar
• NIELSEN J, JOHANSEN K, YDE H: The frequency of diabetes mellitus in patients with Turner's syndrome and pure gonadal dysgenesis. Blood glucose, plasma insulin and growth hormone level during an oral glucose tolerance test. Acta Endocrinol Coperth. (1969) 62:251–269.
   Google Scholar
• RANDLE PJ, GARLAND PB, HALES CN, NEWSHOLME EA: The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet (1963) 1:785–789.
   Google Scholar
• FORBES AP ENGEL E: The high incidence of diabetes mellitus in 41 patients with gonadal dysgenesis, and their close relatives. Metabolism (1963) 12:428–439.
   PubMedGoogle Scholar
• POLYCHRONAKOS C, LETARTE J, COLLU R, DUCHARME JR: Carbohydrate intolerance in children and adolescents with Turner syndrome. Pediatr. (1980) 96:1009–1014.
   Google Scholar
• COSTIN G, KOGUT MD: Carbohydrate intolerance in gonadal dysgenesis: evidence for insulin resistance and hyperglucagonemia. Horm. Res. (1985) 22:260–269.
   PubMedGoogle Scholar
• STEVENSON JC, CROOK D, IF, LEES B, WHITEHEAD MI: Oral versus transdermal hormone replacement therapy. Int. J Feral. Menopausal. Stud. (1993) 38\(Suppl. 1):30–35.
   Google Scholar
• LUOTOLA H, PYORALA T, LOIKKANEN M: Effects of natural oestrogen/progestogen substitution therapy on carbohydrate and lipid metabolism in post-menopausal women. Maturitas (1986) 8(3):245–253.
   PubMedGoogle Scholar
• TONSTAD S, OSE L, GORBITZ C, DJOSELAND 0, BARD JM, FRUCHART JC: Efficacy of sequential hormone replacement therapy in the treatment of hypercholesterolaemia among postmenopausal women. J Intern. Med. (1995) 238(1):39–47.
   PubMedGoogle Scholar
• BUSH TL, BARRETT CONNOR E, COWAN LD et al: Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation (1987) 75(6):1102–1109.
   PubMed Web of Science ®Google Scholar
• BARRETT CONNOR E, LAAKSO M: Ischemic heart disease risk in postmenopausal women. Effects of estrogen use on glucose and insulin levels. Arteriosclerosis (1990) 10(4):531–534.
   Google Scholar
• NABULSI AA, FOLSOM AR, WHITE A et al: Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. The Atherosclerosis Risk in Communities Study Investigators. N Engl. J. Med. (1993) 328(15):1069–1075.
   Google Scholar
• STOPPOLONI G, PRISCO E ALFANO, IAFUSCO D, MARRAZZO G, PAOLISSO G: Characteristics of insulin resistance in Turner syndrome. Dialler Metab. (1990) 16:267–271.
   PubMedGoogle Scholar
• CAPRIO S, BOULWARE S, DIAMOND etal.: Insulin resistance: an early metabolic defect of Turner's syndrome. J Endocrinol Metab. (1991) 72:832–836.
   Google Scholar
• RASIO E, ANTAKI A, VAN J: Diabetes mellitus in gonadal dysgenesis: studies of insulin and growth hormone secretion. Eur. I Clin. Invest. (1976) 6:59–66.
   PubMedGoogle Scholar
• BAILEY CJ, AHMED SOROUR H: Role of ovarian hormones in the long-term control of glucose homeostasis. Effects of insulin secretion. Diabetologia (1980) 19(5):475–481.
   PubMedGoogle Scholar
• KUMAGAI S, HOLMANG A, BJORNTORP P: The effects of oestrogen and progesterone on insulin sensitivity in female rats. Acta Physic] Scam/. (1993) 149(1):91–97.
   PubMedGoogle Scholar
• SYLVEN L, HAGENFELDT K, BRONDUM NK, VON SCHOULTZ B: Middle-aged women with Turner's syndrome. Medical status, hormonal treatment and social life. Acta Endocrinol (1991) 125:359–365.
   PubMedGoogle Scholar
• GARDNER LI: Letter: Intrahepatic bile stasis in 45,X Turner's syndrome. N Engl. J Med. (1974) 290:406–406.
   PubMedGoogle Scholar
• KRIVOSHEEV AB: [Development of liver cirrhosis in a female patient with Shereshevskii-Turner syndrome]. KIM. Med. Mask. (1990) 68:95–96.
   Google Scholar
• CHETKOWSKI RJ, MELDRUM DR, STEINGOLD KA et al.: Biologic effects of transdermal estradiol. N Engl. J. Med. (1986) 314:1615–1620.
   PubMed Web of Science ®Google Scholar
• JOSPE N, ORLOWSKI CC, FURLANETTO RW: Comparison of transdermal and oral estrogen therapy in girls with Turner's syndrome. J. Pediatr. Endocnriol. Metab. (1995) 8:111–116.
   PubMed Web of Science ®Google Scholar
• VERDECCHIA P, SCHILLACI G, GATTESCHI C et al: Blunted nocturnal fall in blood pressure in hypertensive women with future cardiovascular morbid events. Circulation (1993) 88(3):986–992.
   PubMed Web of Science ®Google Scholar
• VERDECCHIA P, SCHILLACI G, BOLDRINI F, GUERRIERI M, PORCELLATI C: Sex, cardiac hypertrophy and diurnal blood pressure variations in essential hypertension. J. Hypertens. (1992) 10(7):683–692.
   PubMedGoogle Scholar
• VERDECCHIA P, SCHILLACI G, GUERRIERI M et al.: Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension. Circulation (1990) 81 (2) :5 28–53 6 .
   Google Scholar
• VAN DER HAUWAERT LG, FRYNS JP, DUMOULIN M, LOGGHE N: Cardiovascular malformations in Turner's and Noonan's syndrome. Br. Heart. J. (1978) 40:500–509.
   PubMedGoogle Scholar
• LIPPE B: Turner syndrome. Endombol. Metab. OM. North Am. (1991) 20:121–152.
   PubMed Web of Science ®Google Scholar
• BERDAHL LD, WENSTROM KD, HANSON JW: Web neck anomaly and its with congenital heart disease.Am. J Med. Genet. (1995) 56:304–307.
   PubMed Web of Science ®Google Scholar
• LACRO RV, JONES KL, BENIRSCHKE K: Coarctation of the aorta in Turner syndrome: a pathologic study of fetuses with nuchal cystic hygromas, hydrops fetalis, and female genitalia. Pediatrics (1988) 81:445–451.
   PubMed Web of Science ®Google Scholar
• CLARK EB: Neck web and congenital heart defects: a pathogenic association in 45 X-0 Turner syndrome? teratology (1984) 29:355–361.
   PubMedGoogle Scholar
• ROSS JL, FEUILLAN P, LONG LM, KOWAL K, KUSHNER H, CUTLER GBJ: Lipid abnormalities in Turner syndrome. J. Pediatr. (1995) 126:242–245.
   PubMed Web of Science ®Google Scholar
• GRAVHOLT CH, KLAUSEN IC, WEEKE J, CHRISTIANSEN JS: Lp(a) and lipids in adult Turner's syndrome: impact of treatment with 17beta-estradiol and norethisterone. Atherosclerosis (2000) 150:201–208.
   PubMedGoogle Scholar
• MAZZANTI L, CACCIARI E: Congenital heart disease in patients with Turner's syndrome. Italian Study Group for Turner Syndrome (ISGTS). I Pediatr. (1998) 133(5):688–692.
   Google Scholar
• PRANDSTRALLER D, MAZZANTI L, PICCHIO FM et al: Turner's syndrome: cardiologic profile according to the different chromosomal patterns and long-term clinical follow-up of 136 nonpreselected patients. Pediatr. Cardiol (1999) 20(2):108–112.
   PubMedGoogle Scholar
• MAURAS N: Estrogens do not affect whole-body protein metabolism in the prepubertal female. J. Clin. Endombol. Metab. (1995) 80(10):2842–2845.
   PubMedGoogle Scholar
• IVARSSON SA, ERICSSON UB, NILSSON KO et al: Thyroid autoantibodies, Turner's syndrome and growth hormone therapy. Acta Paediatr. (1995) 84:63–65.
   PubMedGoogle Scholar
• VAN CAMPENHOUT J, ANTAKI A, RASIO E: Diabetes mellitus and thyroid autoimmunity in gonadal dysgenesis. Fertil. Steril. (1973) 24:1–9.
   PubMedGoogle Scholar
• WILLIAMS ED, ENGEL E, FORBES AP: Thyroiditis and gonadal dysgenesis. N Engl. J Med. (1964) 270:805–810.
   PubMedGoogle Scholar
• PAI GS, LEACH DC, WEISS L, WOLF C, VAN DYKE DL: Thyroid abnormalities in 20 children with Turner syndrome. J. Pediatr. (1977) 91:267–269.
   PubMedGoogle Scholar
• BRIGHT GM, BLIZZARD RIVI, KAISER DL, CLARKE WL: Organ-specific autoantibodies in children with common 1646 Expert Op/n. Pharmacother. (2001) 2(10) diseases. 1. Pediatr. (1982) 100:8–14.
   Google Scholar
• GERMAIN EL, PLOTNICK LP: Age-related anti-thyroid antibodies and thyroid abnormalities in Turner syndrome. Acta Paediatr. Scalar/. (1986) 75:750–755.
   PubMedGoogle Scholar
• FLEMING S, COWELL C, BAILEY J, BURROW GN: Hashimoto's disease in Turner's syndrome. Chit. Invest. Med. (1988) 11:243–246.
   Google Scholar
• GRUNEIRO PL, IORCANSKY S, COCO R, RIVAROLA MA, BERGADA C: High incidence of thyroid disturbances in 49 children with Turner syndrome. 1. Pediatr. (1987) 111:258–261.
   Google Scholar
• RADETTI G, MAZZANTI L, PAGANINI et al.: Frequency, clinical and laboratory features of thyroiditis in girls with Turner's syndrome. The Italian Study Group for Turner's Syndrome. Acta Paediatr. (1995) 84:909–912.
   Google Scholar
• MARNER B, BILLE G, CHRISTY M et al.: Islet cell cytoplasmic antibodies (ICA) in diabetes and disorders of glucose tolerance. Diabet. Med. (1991) 8:812–816.
   PubMedGoogle Scholar
• LARIZZA D, MARTINETTI BIANCHI, LORINI R et al.: Autoimmunity, HLA, Gm and Km polymorphisms in Turner's syndrome. Autoimmunih, (1989) 4:69–78.
   PubMedGoogle Scholar
• CHIOVATO L, LARIZZA D, BENDINELLI G et al.: Autoimmune hypothyroidism and hyperthyroidism in patients with Turner's syndrome. Eur. Endocrine]. (1996) 134:568–575.
   PubMed Web of Science ®Google Scholar
• DEAN JW, FOWLER PB: Exaggerated responsiveness to thyrotrophin releasing hormone: a risk factor in women with coronary artery disease. Br Med. 1 (1985) 290:1555–1561.
   PubMed Web of Science ®Google Scholar
• AREM R, PATSCH W: Lipoprotein and levels in subclinical hypothyroidism. Effect of levothyroxine therapy. Arch. Intern. Med. (1990) 150:2097–2100.
   PubMedGoogle Scholar
• AREM R, ESCALANTE D: In: Subclinical hypothyroidism: epidemiology, diagnosis and significance. Mosby, St. Louis, MO, USA (1996):213–250.
   Google Scholar
• REAVEN GM: Banting lecture 1988. Role of insulin resistance in human disease. Diabetes (1988) 37:1595–1607.
   PubMed Web of Science ®Google Scholar
• NAERAA RW, GRAVHOLT CH, HANSEN J, NIELSEN J, JUUL S: In: Mortality in Turner syndrome. Albertsson-Wikland K, Ranke MB (Eds.), Elsevier, Amsterdam (1995):323–323.
   Google Scholar
• PRICE WH, CLAYTON JF, COLLYER S, DE MEY R, WILSON J: Mortality ratios, life expectancy, and causes of death in patients with Turner's syndrome. 1. Epidemiel Community Health (1986) 40:97–102.
   Google Scholar
• SCARFI MR, PRISCO F, BERSANI F et al.: Spontaneous and mitomycin-C-induced micronuclei in lymphocytes from subjects affected by Turner's syndrome. Mutat. Res. (1996) 357(1-2):183–190.
   PubMedGoogle Scholar
• ELLISON JW, WARDAK Z, YOUNG MF, ROBEY PG, LAIG-WEBSTER M, CHIONG W: PHOG, a candidate gene for involvement in the short stature of Turner syndrome. Hum. Mel Genet. (1997) 6(8):1341–1347.
   PubMedGoogle Scholar
• RAO E, WEISS B, FUKAMI M et al: Pseudoautosomal deletions encompassing a novel homeobox gene cause growth failure in idiopathic short stature and Turner syndrome. Nat. Genet. (1997) 16(1):54–63.
   PubMed Web of Science ®Google Scholar
• FANG J, DAGENAIS SL, ERICKSON RP et al: Mutations in FOXC2 (MFH-1), a forkhead family transcription factor, are for the hereditary lymphedema-distichiasis syndrome. Am. 1. Hum. Genet. (2000) 67(6):1382–1388.
   Google Scholar
• PHILLIPS DI, BARKER DJ, HALES CN, HIRST S, OSMOND C: Thinness at birth and insulin resistance in adult life. Diabetologia (1994) 37(2):150–154.
   PubMedGoogle Scholar
• COOK JT, LEVY JC, PAGE RC, SHAW JA, HATTERSLEY AT, TURNER RC: Association of low birth weight with beta cell function in the adult first degree relatives of non-insulin dependent diabetic subjects. Br Med. J. (1993) 306(6873):302–306.
   PubMedGoogle Scholar
• PHIPPS K, BARKER DJ, HALES CN, FALL CH, OSMOND C, CLARK PM: Fetal growth and impaired glucose tolerance in men and women. Diabetologia (1993) 36(3):225–228.
   PubMedGoogle Scholar
• ROBINSON S, WALTON RJ, CLARK PM, BARKER DJ, HALES CN, OSMOND C: The relation of fetal growth to plasma glucose in young men. Diabetologia (1992) 35(5):444–446.
   PubMedGoogle Scholar
• HALES CN, BARKER DJ, CLARK PM et al.: Fetal and infant growth and impaired glucose tolerance at age 64. Br Med. I (1991) 303(6809):1019–1022.
   PubMed Web of Science ®Google Scholar
• KVEIBORG M, GRAVHOLT CH, KASSEM M: Evidence of a normal mean telomere fragment length in patients with Ulbrich-Turner syndrome. Eur. 1. Hum. Genet. (In Press).
   Google Scholar